Excelsior Biopharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	898.26	861.91	771.56	671.76	1,338
Revenue Growth (YoY)	4.22%	11.71%	14.86%	-49.81%	-7.29%
Cost of Revenue	538.1	479.82	464.63	384.59	1,045
Gross Profit	360.17	382.1	306.93	287.17	293.35
Selling, General & Admin	438.24	377.21	324.57	277.82	241.65
Research & Development	96.09	83.62	62.51	42.32	56
Operating Expenses	531.77	463.07	388.06	316.47	302.12
Operating Income	-171.6	-80.97	-81.13	-29.29	-8.77
Interest Expense	-7.77	-8.02	-6.37	-4.35	-4.54
Interest & Investment Income	1.26	3.42	5.24	4.17	0.41
Earnings From Equity Investments	2.18	0.25	-	-	-
Currency Exchange Gain (Loss)	-2.53	-4.94	-1.55	-1.28	1.81
Other Non Operating Income (Expenses)	6.16	2.87	1.86	3.68	0.9
EBT Excluding Unusual Items	-172.3	-87.39	-81.95	-27.06	-10.19
Gain (Loss) on Sale of Assets	-0.65	-	-	-	-
Other Unusual Items	0.6	0	-	1.07	0.16
Pretax Income	-172.34	-87.39	-81.95	-25.99	-10.03
Income Tax Expense	10.83	11.32	9.06	7.76	5.62
Net Income	-183.17	-98.71	-91.01	-33.76	-15.65
Net Income to Common	-183.17	-98.71	-91.01	-33.76	-15.65
Shares Outstanding (Basic)	46	46	46	46	47
Shares Outstanding (Diluted)	46	46	46	46	47
Shares Change (YoY)	0.12%	0.42%	0.15%	-1.42%	-5.56%
EPS (Basic)	-3.97	-2.14	-1.98	-0.74	-0.34
EPS (Diluted)	-3.97	-2.14	-1.98	-0.74	-0.34
Free Cash Flow	-175.67	-356.95	-170.41	-2.3	52.95
Free Cash Flow Per Share	-3.81	-7.74	-3.71	-0.05	1.14
Gross Margin	40.10%	44.33%	39.78%	42.75%	21.92%
Operating Margin	-19.10%	-9.40%	-10.51%	-4.36%	-0.66%
Profit Margin	-20.39%	-11.45%	-11.80%	-5.03%	-1.17%
Free Cash Flow Margin	-19.56%	-41.41%	-22.09%	-0.34%	3.96%
EBITDA	-152.62	-65.64	-69.31	-16.41	6.39
EBITDA Margin	-16.99%	-7.62%	-8.98%	-2.44%	0.48%
D&A For EBITDA	18.98	15.33	11.82	12.88	15.15
EBIT	-171.6	-80.97	-81.13	-29.29	-8.77
EBIT Margin	-19.10%	-9.40%	-10.51%	-4.36%	-0.66%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.